Drug Trial Radar · NCT07257978
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 1, 2027
Primary completion
Oct 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- Fenix Innovation GroupIndustry
- Sponsor type
- Industry
- Collaborators
- Neurotech International Limited
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 4 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FENRTT2 study will investigate the efficacy and safety of a medicinal cannabis plant extract with extremely low THC (delta-9-tetrahydrocannabinol), NTI164, on Rett syndrome (RTT) in a crossover design. RTT is a devastating rare genetic condition affecting females and involves debilitating physical and intellectual symptoms. NTI164 is an oil which has demonstrated efficacy in reducing symptoms in several paediatric neurological conditions, including RTT, autism spectrum disorder (ASD), and paediatric acute-onset neuropsychicatric syndrome (PANS). A Phase I/II clinical trial of NTI164 in RTT (FENRTT1/NTIRTT1) showed NTI164 is safe in this population and significantly improved overall clinical severity of illness, as well as core RTT symptoms, including anxiety, mental alertness, communication skills, socialisation/eye contact, and attentiveness. The FENRTT2 study will investigate NTI164 in a larger number of patients, and compare NTI164 to a placebo control. Research tests on patient blood will also be included to further investigate how NTI164 works in the body.
Conditions
- RETT Syndrome With Proven MECP2 Mutation
- Rett Syndrome
Interventions
NTI164Drug
NTI164 is a full-spectrum medicinal cannabis plant extract with \<0.3% THC.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rett Syndrome Behaviour Questionnaire (RSBQ)Time frame: Baseline, Week 12, and Week 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Monash Health
Clayton, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.